Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | O3Se |
| Molecular Weight | 126.96 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | -2 |
SHOW SMILES / InChI
SMILES
[O-][Se]([O-])=O
InChI
InChIKey=MCAHWIHFGHIESP-UHFFFAOYSA-L
InChI=1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)/p-2
The selenite anion is a selenium oxoanion with the chemical formula SeO2−3. A selenite (Se) is a compound that contains this ion. Sodium selenite is an inorganic form of the trace element selenium with potential antineoplastic activity. It was documented that Se deficiency observed in some countries and/or geographic regions (e.g. Keshan region in China), is associated with an increased morbidity and mortality of neoplastic diseases. To correct this problem a number of organic and inorganic selenium compounds were developed and tested. However, it is now firmly established that only an inorganic sodium selenite with four-valent Se, and not that with six-valent (selenate) cation shows anticancer activity. Selenite can undergo redox reaction, for example with protein's sulfhydryl groups expressed on the surface of tumor cells. In this way selenite prevents non-enzymatic formation of parafibrin that coats tumors cells and hence presents them as 'self' to the innate cellular immune system. Consequently, macrophages of the lymphatic system do not recognize neoplastic cells as 'foreign' bodies and spare them from the immune destruction. Sodium selenite also showed promise as a cost-effective, nontoxic anti-inflammatory agent. Treatment with sodium selenite lowers reactive oxygen species (ROS) production, causes a spontaneous reduction in lymphedema volume, increases the efficacy of physical therapy for lymphedema, and reduces the incidence of erysipelas infections in patients with chronic lymphedema. Limited evidence has been presented though that intakes of selenium greater than the amount needed to allow full expression of selenoproteins may have chemopreventive effects against cancer. Controlled intervention studies are needed to fully evaluate selenium as a cancer chemopreventive agent. The US Food and Drug Administration approved a selenium supplement to animal diets; the most common form is sodium selenite for pet foods.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.5 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
200 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sodium selenite and cancer related lymphedema: Biological and pharmacological effects. | 2016-09 |
|
| Nutritional selenium supplements: product types, quality, and safety. | 2001-02 |
|
| Arsenite and cadmium(II) as probes of glucocorticoid receptor structure and function. | 1990-02-05 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11293463
Extradietary supplementation of selenium at the dosage of 200 micrograms per day is generally considered safe and adequate for an adult of average weight subsisting on the typical American diet.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
14124-67-5
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
1090
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
KXO0259XJ1
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
18212
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
9640
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
ALTERNATIVE | |||
|
KXO0259XJ1
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
DTXSID9074517
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY | |||
|
1546398
Created by
admin on Mon Mar 31 20:20:06 GMT 2025 , Edited by admin on Mon Mar 31 20:20:06 GMT 2025
|
PRIMARY |
ACTIVE MOIETY